Healthcare Equipment and Supplies
Company Overview of Sebacia, Inc.
Sebacia, Inc., a medical device company, focuses on creating light-based therapies for the treatment of dermatological conditions. It is developing a device for the treatment of acne. Sebacia, Inc. was formerly known as TIF Acquisition XII, Inc. The company was incorporated in 2008 and is based in Duluth, Georgia.
2905 Premiere Parkway
Duluth, GA 30097
Founded in 2008
Key Executives for Sebacia, Inc.
Chief Executive Officer, President and Director
Vice President of Engineering and Program Management
Compensation as of Fiscal Year 2016.
Sebacia, Inc. Key Developments
Sebacia, Inc. Announces Completion of Enrollment in Pivotal U.S. Clinical Trial for Severe Acne
Oct 7 15
Sebacia, Inc. announced completion of enrollment in the U.S. randomized pivotal clinical trial investigating the use of the Sebacia Acne Treatment System, an investigational device that uses a combination of gold microparticles and laser energy to target acne. Unlike acne treatments that require daily treatments with lotions or pills, the Sebacia System is intended to treat acne through a simple, physician-guided, in-office procedure. Sebacia's proprietary gold microparticles are designed to be used with existing dermatologic lasers to heat the sebaceous glands and follicles to treat acne. The pivotal clinical study is a randomized, blinded, controlled assessment to determine the safety and effectiveness of the Sebacia Acne Treatment System in the treatment of inflammatory acne vulgaris. A total of 396 people were enrolled with 28 dermatologists across the United States. The studies were designed as parallel assignment with one treatment group and two control groups. The control groups received either Sebacia microparticles without laser treatment or the suspension without Sebacia microparticles with laser treatment. Primary outcome measures are the mean percent change in inflammatory lesion count from baseline to week 12 and the safety and tolerability of the procedure. Secondary outcome measures are the mean absolute change in inflammatory lesion count from baseline to week 12 and success by investigator's global assessment (IGA) at week 12. Success is defined as a two-point decrease from baseline IGA. Although accrual is complete, follow up of participants will continue until December 2015.
Sebacia, Inc. Presents at Emerging Medical Technologies Summit, Oct-21-2015 10:00 AM
Oct 7 15
Sebacia, Inc. Presents at Emerging Medical Technologies Summit, Oct-21-2015 10:00 AM. Venue: Sofitel Hotel San Francisco, 223 Twin Dolphin Dr., Redwood City, CA 94065, United States.
Square 1 Bank Announces Credit Facility to Sebacia, Inc
Aug 26 15
Square 1 Bank announced that it has provided a $10 million credit facility to new client Sebacia, Inc. Proceeds will be used to support the company's continued growth.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries